Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 14Pain 13Pain, Postoperative 12Cancer Pain 10Agnosia 7Chronic Pain 6Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Mucositis 3Lung Neoplasms 3Head and Neck Neoplasms 3Supratentorial Neoplasms 2Pancreatic Neoplasms 2Pain, Intractable 2Neoplastic Cells, Circulating 2Multiple Myeloma 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Leukemia 2Inflammation 2Ileus 2Hematologic Neoplasms 2Wounds and Injuries 1Waldenstrom Macroglobulinemia 1Vesico-Ureteral Reflux 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

Nalbuphine 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Nalbuphine Allergy × Morphine × Clear all
NCT05073744 2022-12-29

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Zhongda Hospital

Phase 4 Unknown
316 enrolled

Nalbuphine Allergy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡